In a nutshell This trial is evaluating the safety and effectiveness of allogeneic CAR-T cell therapy (ALLO-715) in patients with multiple myeloma (MM) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This trial is recruiting in Denver, CO. The details Chimeric...
Read MoreIn a nutshell This study aimed to investigate if treatment with inotuzumab ozogamicin in patients with relapsed/unresponsive acute lymphoblastic leukemia was associated with lower healthcare system burden compared to standard of care. This study...
Read More
In a nutshell This study investigated survival rates in advanced non-small cell lung cancer (NSCLC) after nivolumab (Opdivo) treatment. They found that nivolumab was associated with longer survival time in patients that responded to treatment. Some background Lung cancer (LC) is one of the most common cancers worldwide. Non-small...
Read More
In a nutshell This study aimed to investigate the outcomes for patients who underwent allogeneic hematopoietic stem cell transplant after treatment with blinatumomab. This study concluded that survival was driven by the response to study treatment and by salvage status regardless of transplant status. Some...
Read More
In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) for patients with classical Hodgkin’s lymphoma (cHL) that came back after initial treatment. This study concluded that pembrolizumab was effective for these patients, with manageable side effects. Some background First-line chemotherapy is highly...
Read More
In a nutshell This study compared the effectiveness of Kd (carfilzomib, dexamethasone) chemotherapy to Vd (bortezomib, dexamethasone) chemotherapy in patients with multiple myeloma (MM). This study found that Kd improved survival outcomes and had fewer side effects compared to Vd chemotherapy for these patients. Some background Multiple...
Read More
In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....
Read MoreIn a nutshell This study will investigate the effects of nivolumab (Opdivo) and brentuximab vedotin (Adcetris) after stem cell transplant in patients with high risk relapsed or refractory Hodgkin lymphoma (RRHL). The main outcome that will be measured is progression-free survival. This trial is recruiting in multiple locations in the United States. The...
Read More
In a nutshell This study aimed to investigate if the combination of cladribine, cytarabine, and granulocyte colony-stimulating factor (G-CSF) could act as salvage treatment for patients with relapsed or unresponsive acute myeloid leukemia. This study concluded that this treatment was safe and effective in...
Read More
In a nutshell This phase 1/2 trial is examining the effectiveness of liposomal irinotecan (LI; Onivyde) and rucaparib (Rubraca) in treating patients with advanced colorectal cancer. The main outcome to be measured will be the toxicity and tumor response to the treatment. This trial is being conducted in Arizona, Georgia, Minnesota, and Utah, US. The...
Read MoreIn a nutshell This study aimed to investigate the safety of a T-cell therapy, bb2121, for patients with relapsed or unresponsive multiple myeloma. This study concluded that bb2121 shows antitumor activity in these patients. Some background Early studies indicate that bb2121 has potential to treat relapsed or unresponsive...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety of 9-ING-41, for treatment-resistant cancers. The main outcome will be the number of treatment-related adverse events (TRAEs). This trial is recruiting in the United States. The details Some cancers may not respond to conventional treatment. Treatment-resistant cancers are called...
Read More
